Compare

Novartis AG/Fr. NOVN

1D1W1M3M6MYTD1Y5YMAX

About Novartis AG

Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. It operates primarily in the healthcare industry, focusing on the research, development, and manufacturing of a wide range of prescription medications targeting oncology, immunology, neuroscience, and cardiovascular diseases. Key products include Cosentyx (for psoriasis and arthritis) and Entresto (for heart failure). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has a significant geographic presence, with operations in over 100 countries. A key competitive strength of the company is its strong investment in research and development, which underpins its substantial portfolio of innovative therapies.
Ticker
Fr. NOVN
Sector
Health
Primary listing
XSWX
Employees
75,267
Headquarters
Basel, Switzerland
Website
www.novartis.com

Novartis AG Metrics

BasicAdvanced
CHF 242B
23.31
CHF 5.48
0.49
CHF 3.70
2.90%

Bulls say / Bears say

Novartis’s newer medicines are helping offset older-product declines: in Q2, sales grew 43% for Kisqali and Pluvicto, 32% for Kesimpta and 89% for Scemblix. This broad-based momentum helped return the company to sales growth. (SEC)
The FDA approved Pluvicto for an earlier stage of metastatic prostate cancer, expanding its use across metastatic disease and nearly doubling the eligible US patient population. That gives the fast-growing cancer drug room to reach more patients. (Novartis)
Remibrutinib met the main goals in two Phase III trials for relapsing multiple sclerosis, reducing relapse rates versus the comparator drug. Novartis plans to seek regulatory approval, adding a potential new growth product to its pipeline. (SEC)
Generic competition is rapidly eroding sales of Entresto: its Q1 sales fell 42% after US patent expiry, and competition is also affecting other older medicines. Entresto also faces European expiry pressure, adding to the revenue-replacement challenge. (Reuters)
Several important pipeline bets have disappointed: pelacarsen and del-desiran failed late-stage trials, while Novartis halted studies of its rap-cel cell therapy after patient deaths. These setbacks weaken the potential products available to replace sales lost to generics. (Reuters, Reuters)
Novartis still expects core operating income to decline by a low-single-digit rate in 2026, despite low-single-digit sales growth. Its Q2 profit beat was helped by one-off benefits that management expected to reverse as research and launch spending increased in the second half. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.

Funds containing Novartis AG

AllEURUSD
Funds
Fund name
Fund size
Fr. NOVN weighting
iShares MSCI Europe Health Care Sector£ESIH
€890M15.13%
iShares MSCI Europe Health Care Sector€ESIH
€890M15.13%
iShares STOXX Europe 600 Health Care€EXV4
€709M14.93%
iShares STOXX Europe 50€EXW3
€141M6.51%
iShares Edge MSCI Europe Momentum Factor£IEFM
€721M5.22%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.